Name
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeStart With FIRST-LINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
Date & Time
Tuesday, August 18, 2026, 7:00 PM - 8:00 PM
Speakers
Beth Faiman PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO, Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology
Beth Faiman PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO
Description

Learn about the role of BESREMi in the long-term management of polycythemia vera, with insights from Dr Beth Faiman on clinical trial data, disease control, and practical administration considerations.

This is a non-CME event. By registering for this program, you consent to share your registration information with the program's sponsor.

 

Virtual Session Link
View Session